Clinical and Serological Evaluation of a Meningococcal Polysaccharide Vaccine Groups A, C, and Y

Farquhar, John D.; Hankins, William A.; DeSanctis, A. N.; DeMeio, J. L.; Metzgar, D. P.

doi:10.3181/00379727-157-39995

Cited by 15 publications

(8 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The adverse events of fever and injection site reactions reported after receipt of meningococcal vaccine alone were consistent with what was found in the safety and immunogenicity trials during the development of the quadrivalent vaccine [29,30]; they provide further support for a causal link. Systemic adverse events, such as headache and dizziness, may be linked to the vaccine, although such events are routinely reported following administration of placebo in clinical trials, and the high background prevalence of these conditions prevents supporting a causal link in all cases.…”

Section: Discussionsupporting

confidence: 78%

Safety Data on Meningococcal Polysaccharide Vaccine from the Vaccine Adverse Event Reporting System

Ball

Braun

Mootrey

2001

Clinical Infectious Diseases

View full text Add to dashboard Cite

Recent recommendations by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices may lead to the increased use of the meningococcal polysaccharide vaccine. The Vaccine Adverse Event Reporting System (VAERS) is useful for the detection of previously unrecognized reactions and for the monitoring of known reactions. Limitations of VAERS include underreporting and the inability to establish a causal relationship between vaccination and adverse events in most cases. From July 1990 through 31 October 1999, 110 adverse events were reported after receipt of meningococcal vaccine alone. Thirteen (12%) were serious, including 6 injection site reactions, 3 allergic reactions, 1 case of Guillain-Barré syndrome, and 3 miscellaneous events. Fever (30%), headache (17%), dizziness (15%), injection site hypersensitivity (13%), urticaria (12%), and paresthesia (10%) were among the most common events reported. Fever and injection site and allergic reactions are most likely causally linked to the vaccine. That there were few reports of serious adverse events, with >6 million doses having been distributed, and no clear signal of a previously unrecognized serious reaction is reassuring with regard to the safety of meningococcal vaccine.

show abstract

Section: Discussionsupporting

confidence: 78%

Safety Data on Meningococcal Polysaccharide Vaccine from the Vaccine Adverse Event Reporting System

Ball

Braun

Mootrey

2001

Clinical Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…meningitidis as real and fairly common causes of disease (Griffiss et al, 1981), emphasizes the need to develop the capsular polysaccharides of the epidemiologically 'minor' serogroups as potential vaccines. The optimal formulation of a polyvalent meningococcal vaccine may become clearer with the results of human safety and immunogenicity testing of serogroup B, Y, W 135 and 29E capsular polysaccharide vaccines currently underway (Farquhar et al, 1978;Zollinger et al, 1979;Griffiss et al, 1981).…”

Section: Discussionmentioning

confidence: 99%

“…Despite knowledge of the chemical structure of their respective capsular polysaccharides, the immunochemical basis for the cross reaction between the two serogroups has not been investigated. With the development of vaccines against meningococcal serogroups other than A and C (Farquhar et al, 1978 ;Zollinger et al, 1979;Griffiss et al, 1981), the formulation of a polyvalent meningococcal vaccine has become feasible. If the 29Esss induces antibody which lyses Gp Z strains, its inclusion in a polyvalent preparation should provide protection against the latter serogroup (Griffiss, 1982), thus reducing the number of required components.…”

Section: Introductionmentioning

confidence: 99%

Immunological Relationship Between The Capsular Polysaccharides Of Neisseria Meningitidis Serogroups Z and 29E

Mcleod

Brandt

1983

Microbiology

View full text Add to dashboard Cite

The immunological relationship between serogroups 29E and Z of Neisseria meningitidis was investigated using bacterial agglutination, precipitin-in-gel, primary antigen binding and immune lysis assays. The two capsular polysaccharides were both cross immunogenic and cross reactive. Demonstration of the relationship using group Z antisera depended on which assay was used. It was most readily apparent in assays of immune lysis, less apparent when precipitins were sought in gel and inapparent when bacterial agglutination, the standard assay for determining serogroup, was employed. The cross reacting epitope was expressed 10-fold more within the group 29E polysaccharide than within the group Z polysaccharide. These findings imply that inclusion of either polysaccharide in a polyvalent meningococcal vaccine may obviate the need to include the other polysaccharide.

show abstract

“…The results also raise intriguing genetic questions that await explanation. On a more practical level, strain 8021 may be useful for vaccine development, since both serogroup determinants could be prepared from a single seed strain, avoiding the increased reactogenicity inherent in combining polysaccharides from individual preparations (Farquhar et al, 1978). Testing of a strain 8021 capsular polysaccharide vaccine in human volunteers is currently underway to determine its usefulness.…”

Section: R E S U L T S a N D Discussionmentioning

confidence: 99%

Elaboration of Both the Group W135 and Group Y Capsular Polysaccharides by a Single Strain of Neisseria meningitidis

Bl¹,

Gb²,

Dk³

et al. 1980

Microbiology

View full text Add to dashboard Cite

A single strain (8021) of Neisseria meningitidis, isolated from a child with disseminated meningococcal disease, was found to elaborate two serogroup-specific capsular polysaccharides-Y and W135. The original isolate as well as the progeny of ten single colony sub-isolates each agglutinated with both group Y and group W135 serogrouping antisera. The capsular polysccharide of strain 8021 contained the chemical constituents of both the W135 and Y capsular polysaccharides in a ratio of about 2.5:1. The patient responded immunologically to both capsular polysaccharides with haemagglutinating antibodies. Analysis by double diffusion in agar revealed that the capsular polysaccharide of strain 8021 contained individual molecules of group W135 and group Y capsular polysaccharides as well as a mosaic molecule containing both antigenic determinants.

show abstract

Clinical and Serological Evaluation of a Meningococcal Polysaccharide Vaccine Groups A, C, and Y

Cited by 15 publications

References 2 publications

Safety Data on Meningococcal Polysaccharide Vaccine from the Vaccine Adverse Event Reporting System

Safety Data on Meningococcal Polysaccharide Vaccine from the Vaccine Adverse Event Reporting System

Immunological Relationship Between The Capsular Polysaccharides Of Neisseria Meningitidis Serogroups Z and 29E

Elaboration of Both the Group W135 and Group Y Capsular Polysaccharides by a Single Strain of Neisseria meningitidis

Contact Info

Product

Resources

About